GPhA urges Congress to dissolution Medicaid remission penalty

The Generic Pharmaceutical Association (GPhA) sent a minute to a Chairmen and Ranking Members of a Senate Finance Committee and House Energy and Commerce Committee expressing low concerns that a recently enacted Medicaid remission chastisement on general drugs could expostulate adult drug costs and impede studious entrance to some-more affordable medicines. At emanate is Section 602 of a Bipartisan Budget Act (BBA) of 2015, that justification Medicaid remission process to levy a new chastisement on generics for cost increases surpassing acceleration in remission durations commencement in 2017.

“Experts know that general drugs expostulate savings, not costs,” pronounced Chip Davis, President and CEO, GPhA. “This misled sustenance could put billions of dollars in studious assets during risk and should be immediately repealed.”

A Department of Health and Human Services (HHS) ASPE issue brief states “Our examination of justification strongly supports a end that general drug prices are not an critical partial of a drug cost problem confronting a nation. In fact, about two-thirds of general products seem to have gifted cost declines in 2014.”

A new news by AARP, Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2006 to 2013, identifies code and specialty drugs

Article source: